Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NAMPT | P43490 | 9/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PPIB | P23284 | 1/20 | 0.39 |
| ▸ | PPIA | P62937 | 1/20 | 0.39 |
| ▸ | PPID | Q08752 | 1/20 | 0.39 |
| ▸ | PPIG | Q13427 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249197 | 0.83 | KMT2A (0.47) | SMN1; SMN2L3MBTL1KMT2ALMNAHTT | |
| SCHEMBL20249179 | 0.82 | RECQL (0.50) | SMN1; SMN2NAMPTL3MBTL1TRPV1CYP2C9 | |
| SCHEMBL18291355 | 0.79 | NAMPT (0.53) | SMN1; SMN2NAMPTMEN1KMT2APOLB | |
| SCHEMBL27799938 | 0.79 | NAMPT (0.53) | SMN1; SMN2NAMPTL3MBTL1CYP2C9MEN1 | |
| SCHEMBL20037860 | 0.79 | MEN1 (0.42) | SMN1; SMN2NAMPTMEN1KMT2APOLB | |
| SCHEMBL3216761 | 0.75 | KMT2A (0.62) | L3MBTL1TRPV1MEN1KMT2AHTT | |
| SCHEMBL15498266 | 0.74 | CA2 (0.38) | SMN1; SMN2L3MBTL1MEN1KMT2ALMNA | |
| SCHEMBL15215455 | 0.74 | CA12 (0.46) | SMN1; SMN2L3MBTL1LMNAHTT | |
| SCHEMBL3196417 | 0.72 | P2RX7 (0.49) | SMN1; SMN2TRPV1MEN1KMT2A | |
| SCHEMBL16544500 | 0.72 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | SMN1; SMN2 1690/4885NAMPT 256/4885L3MBTL1 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.